C34
Conditions
Interventions
Group 1: Patients who are being or have been treated with a checkpoint inhibitor for metastatic lung cancer.
Sponsors
Universitätsmedizin Göttingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Metastatic lung cancer, therapy with at least one checkpoint inhibitor as monotherapy or in combination with chemotherapy
Exclusion criteria
Exclusion criteria: Therapy in the context of other clinical studies in which the administered active substance is unclear
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is response to checkpoint inhibitors correlated with immune cell score. Response is assessed retrospectively based on the results of the respective staging examinations and the course of the disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| Other factors are considered as secondary endpoints to investigate whether they may be related to the immune cell score and the response to therapy. Other factors are the histological type, mutations (KRAS, MET, TP53), smoking status, possible radiation, etc. All of the above factors are collected retrospectively from the patient files. | — |
Countries
Germany
Contacts
Public ContactAchim Rittmeyer
LKI Lungenfachklinik Immenhausen Pneumologische Lehrklinik der Universitätsmedizin Göttingen
Outcome results
None listed